ED
PLRX icon

Exane Derivatives’s Pliant Therapeutics PLRX Stock Holding History

Exane Derivatives’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$1.87K Sell
234
-5,056
-96% -$32.4K ﹤0.01% 446
2022
Q1 		$37.1K Buy
5,290
+2,319
+78% +$23.7K 0.01% 602
2021
Q4 		$0 Hold
2,971
– – ﹤0.01% 940
2021
Q3 		$48.9K Buy
+2,971
New +$63.1K 0.01% 616

Other funds holding PLRX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return

Exane Derivatives's PLRX Position: Q2 2022 in Review

Exane Derivatives reduced its Pliant Therapeutics (PLRX) stake by 96% in Q2 2022, selling an estimated $32.4K and leaving 234 shares worth $1.87K. The position accounts for ﹤0.01% of the portfolio, ranked #446.

Exane Derivatives first reported a position in PLRX in Q3 2021 and has held it in 4 quarters since. The position peaked at $48.9K in Q3 2021. 88 funds tracked by Wall St. Rank hold PLRX as of Q2 2022.

  • Exane Derivatives held 234 shares of Pliant Therapeutics worth $1.87K as of Q2 2022.
  • Exane Derivatives sold 5,056 Pliant Therapeutics shares in Q2 2022, an estimated $32.4K.
  • Pliant Therapeutics made up ﹤0.01% of Exane Derivatives's portfolio in Q2 2022, its #446 holding.
  • Exane Derivatives first reported a position in Pliant Therapeutics in Q3 2021 and has held it in 4 quarters since.
  • Exane Derivatives's Pliant Therapeutics position peaked at $48.9K in Q3 2021.
  • 88 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2022.

Based on Exane Derivatives's 13F filing for Q2 2022, filed 12 Jul 2022.